ST2 Biomarker Market

ST2 Biomarker Market: Introduction

Cardiac biomarkers are the substances that are released into the bloodstream when the heart is stressed or damaged. Suppression of tumorigenicity 2 (ST2) is one such biomarker used to help in measurement of heart failure risk to assess the treatment options. The ST2 biomarker is a member of the interleukin-1 receptor family biomarker. It is a strong predictor and most promising biomarker for both chronic and acute heart failure.

ST2 was first discovered in 1989, but in 2002 it was known to be expressed by cardiac cells in response to myocardial stress. Unlike other cardiac biomarkers, the level of ST2 in the blood is found the best to help physicians for making decisions for an appropriate action to take and quickly adjust the treatment.

The level of ST2 is quickly changed with the heart conditions of the patients which makes it as a best cardiac biomarker to monitor the progress of the heart treatment. According to the centre for disease control and prevention (CDC), heart disease is the leading cause of death for people in the United States, including African Americans, Hispanics, and whites.

Besides, heart disease is found as the second cause of death in American Indians or Alaska Natives and Asians or Pacific Islanders. However, it is observed that more clinicians are now turning to use ST2 biomarker unlike other biomarkers to help and guide treatment of heart failure of patients. Recently, the Presage ST2 assay has been approved by regulatory agencies in Europe and the United States for prognostication in Heart failure.

Moreover, due to the low-biological variability, ST2 biomarker considered as an ideal biomarker to monitor heart disease. It helps to monitor the risk of heart failure and guide in hospital and post-discharge care of the heart patients.

ST2 Biomarker Market: Drivers and Restraints

Increasing prevalence and incidence of heart diseases drives the ST2 biomarker market. Unlike other biomarkers, ST2 biomarker is considered as an ideal biomarker to monitor heart disease because of the low-biological variability, which drives the market of ST2 biomarker.

Nowadays, the rising heart diseases due to physical inactivity and unhealthy diet are the main factors drives the ST2 biomarker market. However, due to unavailability of sufficient systems/products for the detection of ST2 biomarker and lack of awareness about the use of ST2 biomarker among the clinicians expected to restrain the ST2 biomarker market.

ST2 Biomarker Market: Overview

According to WHO, 17.9 Mn people are dying due to cardiovascular diseases each year, which is approximately 31% of all death worldwide. Consequently, as a novel biomarker for the detection of heart diseases the market of ST2 biomarker will expectedly grow tremendously during forecasting periods.

The ST2 biomarker detection will provide immense opportunities among the key players to develop novel ST2 biomarker detection kits and devices in the upcoming periods. The rising death rate due to heart diseases expected to grow the market of ST2 biomarker globally.

The in time result of ST2 level by the ELISA assay helps physicians to control and manage the heart patients, which is expected to help in the growth of global ST2 biomarker market.

ST2 Biomarker Market: Region-wise Out Look

The U.S. is expected as the leading market of ST2 biomarker due to the increasing prevalence and death of heart disease in this region. The market of ST2 biomarker is high in the U.S. also because of the greater degree of awareness among the individuals and high economy followed by Europe.

The high growth of the ST2 biomarker market has also been observed in Asia Pacific countries due to the increasing number of death due to heart diseases and awareness among the people.

Prominent growth of ST2 biomarker market has been expected from the emerging countries such as China, India, Brazil and South Africa in the forecast years that will provide a huge opportunity to lunch new product among the market players.

ST2 Biomarker Market: Key Players

Examples of some of the key market participants operating in the ST2 biomarker market are Thermo Fisher Scientific, Inc., Critical Care Diagnostics, Inc., Diagnostic Automation/Cortez Diagnostics, Inc., MyBioSource, Inc., San Diego, CA. Elabscience Biotechnology, Inc. among others.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, and inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macro-economic indicators, and governing factors, along with market attractiveness as per segment.

The report also maps the qualitative impact of various market factors on market segments and geographies.

The report covers exhaustive analysis on:

• ST2 Biomarker Market Segments
• ST2 Biomarker Market Dynamics
• ST2 Biomarker Market Size
• ST2 Biomarker Supply & Demand
• ST2 Biomarker Current Trends/Issues/Challenges
• ST2 Biomarker Competition & Companies Involved
• ST2 Biomarker Technology
• ST2 Biomarker Value Chain

Regional analysis includes:

• North America (U.S., Canada)
• Latin America (Mexico, Brazil, Argentina, Peru, Chile, Rest of LATAM)
• Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX, Eastern Europe, Rest of Europe)
• CIS & Russia
• Japan
• Asia Pacific Excluding Japan ( Greater China, India, South Korea, ASEAN Countries, Rest of APEJ)
• The Middle East and Africa (GCC Countries, Turkey, Iran, Israel, S. Africa, Rest of MEA)

ST2 Biomarker Market: Segmentation

Based on techniques used, the ST2 biomarker market can be segmented as:

• ELISA
• Immunochromatography

Based on product types, the ST2 biomarker market can be segmented as:

• Presage ST2 Assay Kit
• ASPECT Plus analyzer

Based on disease types, the ST2 biomarker market can be segmented as:

• Chronic Heart Failure
• Acute Heart Failure
• Myocardial Infarction
• Inflammation
• Macrophage Activation (Fibrosis)

Based on the end-user, the ST2 biomarker market can be segmented as:

• Hospitals
• Cardiology Clinics
• Diagnostic centres
• Pathology Laboratories
• Ambulatory surgical centres
• Home care settings